Synonyms: BLU-667 | BLU667 | Gavreto®
pralsetinib is an approved drug (FDA (2020), EMA (2021))
Compound class:
Synthetic organic
Comment: Pralsetinib (BLU-667) is a second-generation selective RET kinase inhibitor that is being developed by Blueprint Medicines [2]. It is Compound 130 in patent US20170121312A1 and our structure was drawn from the image therein [1]. Selective RET inhibitors have oncology potential for the treatment of solid tumours with oncogenic RET alterations (e.g. constitutively activating RET point mutations and RET gene rearrangements). They are expected to offer more effective anti-tumour efficacy in RET-driven tumours than the currently available multi-kinase inhibitors (such as cabozantinib and vandetanib) that have limited anti-RET activity, and which have exhibited poor therapeutic responses in this defined patient group.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes. FDA (2020) | EMA (2021) |
IUPAC Name ![]() |
N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
11004 | pralsetinib |
Synonyms ![]() |
BLU-667 | BLU667 | Gavreto® |
Database Links ![]() |
|
CAS Registry No. | 2097132-94-8 (source: WHO INN record) |
GtoPdb PubChem SID | 375973221 |
PubChem CID | 129073603 |
Search Google for chemical match using the InChIKey | GBLBJPZSROAGMF-RWYJCYHVSA-N |
Search Google for chemicals with the same backbone | GBLBJPZSROAGMF |
Search PubMed clinical trials | pralsetinib |
Search PubMed titles | pralsetinib |
Search PubMed titles/abstracts | pralsetinib |
UniChem Compound Search for chemical match using the InChIKey | GBLBJPZSROAGMF-RWYJCYHVSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | GBLBJPZSROAGMF-RWYJCYHVSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Pralsetinib (links to external site)
Cat. No. HY-112301 |